Oppenheimer & Co. Inc. grew its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 42.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,080 shares of the financial services provider’s stock after buying an additional 9,552 shares during the quarter. Oppenheimer & Co. Inc. owned 0.06% of iShares Biotechnology ETF worth $6,754,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. IFP Advisors Inc raised its position in iShares Biotechnology ETF by 39.3% in the second quarter. IFP Advisors Inc now owns 49,988 shares of the financial services provider’s stock worth $9,507,000 after purchasing an additional 14,115 shares in the last quarter. Security National Bank of Sioux City Iowa IA lifted its stake in iShares Biotechnology ETF by 31.8% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 12,187 shares of the financial services provider’s stock worth $2,318,000 after purchasing an additional 2,939 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in iShares Biotechnology ETF by 64.0% during the second quarter. The Manufacturers Life Insurance Company now owns 101,838 shares of the financial services provider’s stock valued at $19,369,000 after purchasing an additional 39,760 shares in the last quarter. Kestra Advisory Services LLC boosted its holdings in iShares Biotechnology ETF by 12.2% during the first quarter. Kestra Advisory Services LLC now owns 47,461 shares of the financial services provider’s stock valued at $8,014,000 after purchasing an additional 5,155 shares in the last quarter. Finally, Navellier & Associates Inc. acquired a new stake in iShares Biotechnology ETF during the second quarter valued at approximately $531,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Up 2.0%
IBB stock opened at $216.35 on Thursday. iShares Biotechnology ETF has a 1-year low of $154.62 and a 1-year high of $217.12. The business’s 50 day moving average is $208.27 and its 200-day moving average is $184.36.
iShares Biotechnology ETF Cuts Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were given a dividend of $0.0112 per share. This is a drop from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. The ex-dividend date was Tuesday, September 15th. This represents a $0.04 annualized dividend and a dividend yield of 0.0%.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
